Q4 2019 EPS Estimates for Amedisys Inc Decreased by Analyst (AMED)

Amedisys Inc (NASDAQ:AMED) – SunTrust Banks dropped their Q4 2019 earnings per share (EPS) estimates for Amedisys in a note issued to investors on Wednesday, May 1st, according to Zacks Investment Research. SunTrust Banks analyst D. Macdonald now forecasts that the health services provider will post earnings of $1.11 per share for the quarter, down from their prior forecast of $1.13. SunTrust Banks has a “Buy” rating and a $145.00 price objective on the stock.

Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.22. Amedisys had a net margin of 7.14% and a return on equity of 28.25%. The company had revenue of $467.34 million for the quarter, compared to the consensus estimate of $460.83 million. During the same period in the prior year, the company posted $0.79 EPS. The company’s revenue was up 17.0% compared to the same quarter last year.

A number of other analysts have also recently commented on AMED. BidaskClub cut Amedisys from a “hold” rating to a “sell” rating in a research note on Friday, May 17th. ValuEngine cut Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, May 14th. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $151.00 price target for the company in a research note on Thursday, February 7th. Craig Hallum lowered their price target on Amedisys from $132.00 to $124.00 and set a “hold” rating for the company in a research note on Friday, March 1st. They noted that the move was a valuation call. Finally, Raymond James raised Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 price target for the company in a research note on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $125.90.

Shares of AMED stock traded up $3.57 on Monday, reaching $112.34. The company had a trading volume of 466,523 shares, compared to its average volume of 460,487. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.91. The stock has a market cap of $3.60 billion, a PE ratio of 30.95, a price-to-earnings-growth ratio of 1.38 and a beta of 1.33. Amedisys has a 12 month low of $73.97 and a 12 month high of $140.91.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Alpha Quant Advisors LLC boosted its position in Amedisys by 137.0% during the 1st quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock worth $29,000 after acquiring an additional 137 shares during the last quarter. Financial Gravity Companies Inc. acquired a new position in Amedisys during the 4th quarter worth approximately $50,000. Advantage Investment Management LLC acquired a new position in Amedisys during the 1st quarter worth approximately $48,000. First Hawaiian Bank boosted its position in Amedisys by 45.6% during the 4th quarter. First Hawaiian Bank now owns 415 shares of the health services provider’s stock worth $49,000 after acquiring an additional 130 shares during the last quarter. Finally, Meeder Asset Management Inc. boosted its position in Amedisys by 107.4% during the 4th quarter. Meeder Asset Management Inc. now owns 477 shares of the health services provider’s stock worth $56,000 after acquiring an additional 247 shares during the last quarter. 86.32% of the stock is owned by institutional investors and hedge funds.

In other Amedisys news, Director Bruce D. Perkins bought 2,500 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was acquired at an average cost of $111.84 per share, with a total value of $279,600.00. Following the purchase, the director now owns 22,088 shares in the company, valued at $2,470,321.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David L. Kemmerly sold 5,000 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $109.96, for a total value of $549,800.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,281 shares of company stock valued at $2,710,043. 2.90% of the stock is owned by company insiders.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Recommended Story: Quiet Period

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.